KalVista Pharmaceuticals
KALVKALV · Stock Price
Historical price data
Overview
KalVista Pharmaceuticals is a mission-driven biotech focused on developing oral therapies for rare diseases with significant unmet need, beginning with hereditary angioedema (HAE). The company has successfully transitioned to a commercial entity with the FDA approval and launch of EKTERLY®, a first-in-class oral on-demand therapy for HAE attacks. Its strategy leverages a proprietary small molecule platform targeting the kallikrein-kinin system to expand its HAE portfolio into prophylaxis and explore new indications in thrombosis and inflammation.
Technology Platform
Oral small molecule platform focused on inhibiting key proteases in the kallikrein-kinin system (KKS), including plasma kallikrein and Factor XIIa, for the treatment of rare inflammatory diseases and beyond.
Pipeline
13| Drug | Indication | Stage | Watch |
|---|---|---|---|
| KVD900 600 mg + KVD900 300 mg | Hereditary Angioedema | Phase 3 | |
| Placebo + KVD900 600 mg + KVD900 300 mg | Hereditary Angioedema | Phase 3 | |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | Hereditary Angioedema | Phase 3 | |
| KVD900 600 mg + Drug: KVD900 300 mg | Hereditary Angioedema | Phase 3 | |
| KVD001 Injection | Diabetic Macular Edema | Phase 2 |
Funding History
4FDA Approved Drugs
1
Company Timeline
Founded in Cambridge, United States
Series B: $35.0M
IPO — $60.0M
PIPE: $75.0M
FDA Approval: EKTERLY